Evidence-Based Complementary and Alternative Medicine / 2022 / Article / Tab 2 / Research Article
[Retracted] Potential Use of Anti-Cancer Drugs for Treatment of Preeclampsia by Targeting the miRNA-IGF1R-PI3K-AKT Axis Table 2 Plot of nanoparticle size with respect to time, recorded over a 90 s period. The error bars represent the standard deviation of measurements for 20 particles in five separate sample runs (n = 100).
Pert_iname Cell_iname Pert_idose Pert_itime (h) Moa Target_name TAG AS-605240 LNCAP 1.11 μ M 24 PI3K inhibitor PIK3CG −1.6199 GDC-0941 HME1 0.12 μ M 3 PI3K inhibitor PIK3CG|PIK3CA|PIK3CB|PIK3CD −1.6038 Taselisib BJAB 0.01 μ M 24 PI3K inhibitor PIK3CA|PIK3CB|PIK3CD|PIK3CG −1.5581 Alpelisib OCILY3 0.01 μ M 24 PI3K inhibitor PIK3CA|PIK3CB|PIK3CD|PIK3CG −1.5362 SAR-245409 MDAMB231 0.04 μ M 24 PI3K inhibitor MTOR|PIK3CG −1.5214 Buparlisib MCF7 0.03 μ M 24 PI3K inhibitor PIK3CA|PIK3CG −1.5214 XL-147 A549 0.125 μ M 24 PI3K inhibitor PIK3CG|PIK3CA|PIK3CD −1.5164 Taselisib OCILY19 0.01 μ M 24 PI3K inhibitor PIK3CA|PIK3CB|PIK3CD|PIK3CG −1.5109 Idelalisib HBL1 2.5 μ M 24 PI3K inhibitor PIK3CD|PIK3CG|CCL3|CCL4|PIK3CA|PIK3CB −1.5063 AZD-5363 HA1E 2.22 μ M 24 AKT inhibitor AKT1|AKT2|AKT3 −1.5825 MK-2206 OCILY19 0.04 μ M 4 AKT inhibitor AKT1|AKT2|AKT3 −1.5567 GDC-0068 THP1 0.03 μ M 24 AKT inhibitor AKT1|AKT2|AKT3|CYP3A5|PRKG1 −1.5259 GDC-0068 A375 2.22 μ M 24 AKT inhibitor AKT1|AKT2|AKT3|CYP3A5|PRKG1 −1.5081 MK-2206 MCF10 A 0.12 μ M 24 AKT inhibitor AKT1|AKT2|AKT3 −1.5067 AZD-5363 PC3 1.11 μ M 24 AKT inhibitor AKT1|AKT2|AKT3 −1.502 TAK-285 HELA 0.08 μ M 24 EGFR inhibitor ERBB2|EGFR −1.5618 Afatinib AGS 1.11 μ M 24 EGFR inhibitor EGFR|ERBB2|ERBB4 −1.5531 AZD-9291 A375 1.11 μ M 24 EGFR inhibitor EGFR −1.5492 Erlotinib MCF10 A 3.33 μ M 24 EGFR inhibitor EGFR|NR1I2 −1.5471 Erlotinib MCF7 0.125 μ M 24 EGFR inhibitor EGFR|NR1I2 −1.5197 Gefitinib K562 2.5 μ M 24 EGFR inhibitor EGFR|CYP2C19 −1.5159 Gefitinib MCF7 0.37 μ M 6 EGFR inhibitor EGFR|CYP2C19 −1.5051 LY-2228820 A375 3.33 μ M 24 P38 MAPK inhibitor MAPK14 −1.6021 TAK-715 NPC 0.04 μ M 24 P38 MAPK inhibitor MAPK14|TNF −1.6019 TAK-715 SKBR3 10 μ M 24 P38 MAPK inhibitor MAPK14|TNF −1.5371 LY-2228820 HELA 0.08 μ M 24 P38 MAPK inhibitor MAPK14 −1.5273 TAK-715 MCF7 1.11 μ M 6 P38 MAPK inhibitor MAPK14|TNF −1.5041
